Temporal evolution of minimally invasive pediatric urolithiasis treatment over 30 years.

J Pediatr UrolJun 30, 2026 (epub)
Clinical ResearchUrology

Lukas Costa de Salles, Arthur Akio Konno Saito, Rafael Bresler et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the evolution of surgical treatments for pediatric urolithiasis over 30 years, analyzing 123 publications and 15,878 procedures. It found a decline in the use of Extracorporeal Shockwave Lithotripsy (ESWL) despite positive outcomes, with increasing interest in miniaturized techniques and flexible ureteroscopy, particularly in Asia, Europe, and North America.

Key findings

  • The number of studies on miniaturized percutaneous techniques and flexible ureteroscopy has increased significantly.
  • Extracorporeal Shockwave Lithotripsy (ESWL) is experiencing a decline in popularity despite positive results.
  • The review analyzed 123 publications and 15,878 procedures, marking a substantial dataset in the field.

Why it matters

Understanding the trends in pediatric urolithiasis treatment is crucial for clinicians to make informed decisions about surgical options and to recognize the shifting landscape of treatment preferences influenced by technological advancements.

Source

PubMed · PMID 42447802

Published in J Pediatr Urol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.